WANG Qi-zhao�� DIAO Yong�� L�� Ying-hui�� LI Zhao-fa�� WANG Li-qiang�� XU Rui-an*
Institute of Molecular Medicine�� Huaqiao University�� Molecular Medicine Engineering Research Center�� Ministry of Education�� Quanzhou 362021�� China
Abstract��
OBJECTIVE Kallistatin (Kal) is a new endogenous anti-angiogenic factor. It also has a role in anti-inflammation and anti-oxidation. Moreover�� it could directly inhibit the proliferation of cancer cells. The aim of this study is to enhance the activities of this multi-functional gene. METHODS Kal together with other genes was co-transfected into cells using lipofectamine 2000 (Lipo)�� and the cell activities were measured via MTT�� scratch�� transwell and tube formation assays. RESULTS It was found that Kal could inhibit the growth of A549�� NCI-H446 and SPC-A1 cells in vitro. The combination of Kal with Trail or vasostatin(Vas) improved the growth inhibitive effect on SPC-A1 cells�� but the combination of these three genes failed to further enhance this phenomenon. Moreover�� combination of Kal with angiostatin (Ang) or Vas�� two other anti-angiogenic factors�� enhanced the anti-cancer and anti-angiogenic activities of Kal for EVC304 cells. The combination of the three genes had the most significant activities. CONCLUSION The activities of Kal can be enhanced by using multigene co-transfenction. This study has provided valuable experimental data for the further application of cancer multigene therapy.
WANG Qi-zhao,
DIAO Yong,
L�z Ying-hui etc
.Enhancing the Anti-Cancer Activities of Kallistatin via Multigene Co-Transfection[J] Chinese Pharmaceutical Journal, 2011,V46(23): 1805-1810
��
[1]
CHAO J�� CHAI K X�� CHEN L M�� et al. Purification�� characterization�� and distribution in normotensive and spontaneously hypertensive rats[J]. J Biol Chem�� 1990�� 265(27)�� 16394-16401. [2] ZHOU G X�� CHAO L�� CHAO J. Kallistatin�� a novel human tissue kallikrein inhibitor. In�� Purification�� characterization�� and reactive center sequence[J]. J Biol Chem�� 1992�� 267(36)�� 25873-25880. [3] MIAO R Q�� AGATA J�� CHAO L�� et al. Kallistatin is a new inhibitor of angiogenesis and tumor growth[J]. Blood�� 2002�� 100(9)�� 3245-3252. [4] MIAO R Q�� CHEN V�� CHAO L�� et al. Structural elements of kallistatin required for inhibition of angiogenesis[J]. Am J Physiol Cell Physiol�� 284(6)�� 1604-1613. [5] DIAO Y�� MA J�� XIAO W�� et al. Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin[J]. World J Gastroenterol�� 2007�� 13(34)�� 4615-4619. [6] TSE L Y�� SUN X�� JIANG H�� et al. Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas[J]. J Gene Med�� 2008�� 10(5)�� 508-517. [7] DEVANI M�� VECCHI M�� FERRERO S�� et al. Kallikrein-kinin system in inflammatory bowel diseases�� Intestinal involvement and correlation with the degree of tissue inflammation[J]. Dig Liver Dis�� 2005�� 37(9)�� 665-673. [8] WANG C R�� CHEN S Y�� WU C L�� et al. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation[J]. Arthritis Rheum�� 52(4)�� 1319-1324. [9] CHAO J�� YIN H�� YAO Y Y�� et al. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation[J]. Hum Gene Ther�� 2006�� 17(12)�� 1201-1213. [10] SHEN B�� HAGIWARA M�� YAO Y Y�� et al. Salutary effect of kallistatin in salt-induced renal injury�� inflammation�� and fibrosis via antioxidative stress[J]. Hypertension�� 2008�� 51(5)�� 1358-1365. [11] HSIEH J L�� SHEN P C�� SHIAU A L�� et al. Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection[J]. Hum Gene Ther�� 2009�� 20��2���� 147-158. [12] HUANG X�� WANG X�� DONG H�� et al. High level expression of recombinant human kallistatin in Pichia pastoris and its bioactivity[J]. Chin J Biotech(���﹤��ѧ��)�� 2010�� 26(2)�� 249-255. [13] JIANG X�� LI H�� QIAO H�� et al. Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice[J]. Cancer Sci�� 2009�� 100(11)�� 2226-2233. [14] SUN X�� KRISSANSEN G W�� FUNG P W C�� et al. Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver[J]. Int J Cancer�� 2005�� 113(4)�� 670-677. [15] JIANG H�� MENG Q�� TAN H�� et al. Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas[J]. Int J Cancer�� 2007�� 121(2)�� 416-424. [16] SUN X�� QIAO H�� JIANG H�� et al. Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors[J]. Cancer Gene Ther�� 2005�� 12(1)��35-45. [17] XU R�� SUN X�� TSE L Y�� et al. Long-term expression of angiostatin suppresses metastatic liver cancer in mice[J]. Hepatology�� 2003�� 37(6)��1451-1460. [18] YAO L��PIKE S E��PITTALUGA S��et al. Antitumor activities of the angiogenesis inhibitors interferon -inducible protein-10 and the calreticulin fragment vasostatin[J]. Cancer Immunol Immunother�� 2002�� 51(7)�� 358-366. [19] YAO L�� PIKE S E�� SETSUDA J�� et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12[J]. Blood�� 2000�� 96�� 1900-1905. [20] CAI K X�� TSE L Y�� LEUNG C�� et al. Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin[J]. Clin Cancer Res�� 2008�� 14(3)�� 939-949. [21] DIAO Y�� MA J�� LI X�� et al. Construction and activity of recombinant adeno-associated virus expressing vasostatin[J]. Chin J Biotech(���﹤��ѧ��)�� 2008�� 24(11)�� 1949-1954. [22] FOLKMAN J. Angiogenesis�� an organizing principle for drug discovery[J]. Nat Rev Drug Discov�� 2007�� 6(4)�� 273-286. [23] SHI J�� ZHENG D�� MAN K�� et al. TRAIL�� a potential agent for cancer therapy[J]. Curr Mol Med�� 2003�� 3(8)�� 727-736. [24] SHI J�� ZHENG D�� LIU Y�� et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice[J]. Cancer Res�� 2005�� 65(5)�� 1687-1692. [25] MA H�� LIU Y�� LIU S�� et al. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice[J]. Hepatology�� 2005�� 42(6)�� 1355-1363. [26] MA H�� LIU Y�� LIU S�� et al. Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors[J]. Int J Cancer�� 2005�� 116(2)�� 314-321. [27] LUO J�� SOLIMINI N L�� ELLEDGE S J. Principles of cancer therapy�� oncogene and non-oncogene addiction[J]. Cell�� 2009�� 136(5)��823-837. Erratum in�� Cell�� 2009�� 138(4)��807. [28] SOLIMINI N L�� LUO J�� ELLEDGE S J. Non-oncogene addiction and the stress phenotype of cancer cells[J]. Cell�� 2007�� 130(6)�� 986-988. [29] WEINSTEIN I B�� JOE A. Oncogene addiction[J]. Cancer Res�� 2008�� 68��9���� 3076-3080.
2011, Vol. 46 
